Tarsus Pharmaceuticals, Inc. TARS Operating Lease Liability Payments Due
Operating Lease Liability Payments Due at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due?
- Tarsus Pharmaceuticals, Inc. (TARS) reported operating lease liability payments due of $28.16M in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due increased by 4910.1% year-over-year, from $562K to $28.16M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s operating lease liability payments due has grown at a 97.2% compound annual growth rate (CAGR), from $953K to $28.4M.
- What does operating lease liability payments due mean?
- This represents the total future cash outflows required to satisfy operating lease agreements. It reflects the company's reliance on leased assets rather than owned assets to conduct business operations. Monitoring this helps evaluate the company's operational leverage and fixed cost structure.